The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R ...
Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be ...
Oct. 31, 2024 — A research team has found that giving iron supplements to children living with human immunodeficiency virus (HIV) in sub-Saharan Africa could be an ... Kidney Transplantation ...
This is a news collection page for Canberra. Check this page for latest news headlines covering major stories, events from Canberra and surrounding ACT. Get breaking news faster than any other ...
GSK reported positive results from its phase three ‘DREAMM-7’ trial on Thursday, highlighting a significant overall survival ...
UK drugmaker GSK might be trading lower following Thursday’s nomination of vaccine sceptic Robert F Kennedy Jr as the USA’s ...
AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...
GSK has announced positive headline interim analysis outcomes from a Phase III trial, which is evaluating Blenrep (belantamab ...
LONDON, UK I 14, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive headline results from a planned interim analysis of the DREAMM-7 ...
GSK announced that belantamab mafodotin (Blenrep) plus bortezomib (Velcade) and dexamethasone improved overall survival in ...
On Thursday, GSK plc (NYSE:GSK) released headline results from a planned interim analysis of the DREAMM-7 head-to-head phase ...
In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...